XBIT.US – XBiotech Inc

Last Day

Biotechnology

• Trailing PE:
• Forward PE:
• Price Sales TTM:
• Price Book MRQ:
• Enterprise Value:
• Enterprise Value Revenue:
• Enterprise Value Ebitda:
• Beta:

• Shares Outstanding:
• Market Capitalization:
• Market Capitalization Mln:
• EBITDA:
• PE Ratio:
• PEG Ratio:
• Wall Street Target Price:
• Book Value:
• Dividend Share:
• Dividend Yield:
• Earnings Share:
• EPS Estimate Current Year:
• EPS Estimate Next Year:
• EPS Estimate Next Quarter:
• EPS Estimate Current Quarter:
• Most Recent Quarter:
• Profit Margin:
• Operating Margin TTM:
• Return On Assets TTM:
• Return On Equity TTM:
• Revenue TTM:
• Revenue Per Share TTM:
• Quarterly Revenue Growth YOY:
• Gross Profit TTM:
• Diluted Eps TTM:
• Quarterly Earnings Growth YOY:

• Type:
• Name:
• Exchange:
• Currency Code:
• Currency Name:
• Currency Symbol:
• Country Name:
• Fiscal Year End:
• IPO Date:
• International Domestic:
• Sector:
• Industry:
• Address:
• Country:
• Listings:
• Web URL:
• Full Time Employees:
• Updated At:
• Gic Sector:
• Gic Group:
• Gic Industry:
• Gic SubIndustry:

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Address: 5217 Winnebago Lane, Austin, TX, United States, 78744